Nakamura Akira, Kubo Tomohiro, Takai Toshiyuki
Department of Experimental Immunology and CREST program of Japan Science and Technology Agency, Institute of Development, Aging and Cancer, Tohoku University, Seiryo 4-1, Sendai 980-8575, Japan.
Adv Exp Med Biol. 2008;640:220-33. doi: 10.1007/978-0-387-09789-3_17.
Fc receptors (FcRs) play an important role in the maintenance of an adequate activation threshold of various cells in antibody-mediated immune responses. Analyses of murine models show that the inhibitory FcR, FcyRIIB plays a pivotal role in the suppression of antibody-mediated allergy and autoimmunity. On the other hand, the activating-type FcRs are essential for the development of these diseases, suggesting that regulation of inhibitory or activating FcR is an ideal target for a therapeutic agent. Recent experimental or clinical studies also indicate that FcRs function as key receptors in the treatment with monoclonal antibodies (mAbs) therapy. This review summarizes FcR functions and highlights possible FcR-targeting therapies including mAb therapies for allergy, autoimmune diseases and cancer.
Fc受体（FcRs）在抗体介导的免疫反应中维持各种细胞的适当激活阈值方面发挥着重要作用。对小鼠模型的分析表明，抑制性FcR，即FcyRIIB，在抑制抗体介导的过敏和自身免疫中起关键作用。另一方面，激活型FcRs对这些疾病的发展至关重要，这表明调节抑制性或激活型FcR是治疗药物的理想靶点。最近的实验或临床研究还表明，FcRs在单克隆抗体（mAbs）治疗中作为关键受体发挥作用。本综述总结了FcR的功能，并强调了可能的以FcR为靶点的治疗方法，包括针对过敏、自身免疫性疾病和癌症的mAb治疗。
